Redwire Corporation has announced a new contract with Aspera Biomedicines, Inc. to conduct space-based research on a novel cancer treatment using Redwire's Pharmaceutical In-space Laboratory (PIL-BOX) technology. The research will focus on analyzing the crystal structure of the protein ADAR1p150, both with and without the drug rebecsinib. The study aims to enhance drug formulation opportunities and expand the range of ADAR1 inhibitors. Rebecsinib, a small molecule ADAR1 inhibitor, has been approved by the U.S. Food and Drug Administration for first-in-human trials. Previous spaceflight experiments have indicated that rebecsinib can inhibit ADAR1 expression, potentially halting the progression of cancer stem cell propagation. This mission is part of a partnership involving NASA, CASIS, and Redwire, and aims to leverage the microgravity environment of the International Space Station to advance cancer treatment research.